Switzerland’s life sciences sector saw a strong year in 2021 with companies contributing to the Covid-19 pandemic and high levels of capital investments being key indicators of the sector’s strength. This is according to the latest edition of the Swiss Biotech Report which was launched by the Swiss Biotech Association.
Eli Lilly and Co’s potential weight-loss drug tirzepatide has shown positive results in a Phase III clinical trial, indicating at the therapy’s potential for patients with obesity and diabetes.
Contract development and manufacturing organisation (CMDO) Matica Biotechnology has opened a new facility for the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
The European Medicines Agency (EMA) has confirmed that the UNICOM’s DADI (Digital Application Dataset Integration) project will now serve as a ‘Plan B’ for the implementation of regulatory data submissions. Amplexor’s Renato Rjavec looks at the opportunities and challenges this presents for pharma companies.
Amphista Therapeutics, a company focused on the development of next generation targeted protein degradation (TPD) therapeutics, has signed a strategic collaboration and license agreement with Bristol Myers Squibb.